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Adult AIDS Clinical Trials Group 5043 examined pharmacokinetic (PK) interactions between amprenavir
(APV) and efavirenz (EFV) both by themselves and when nelfinavir (NFV), indinavir (IDV), ritonavir (RTV),
or saquinavir (SQV) is added. A PK study was conducted after the administration of single doses of APV (day
0). Subjects (n  56) received 600 mg of EFV every 24 h (q24h) for 10 days and restarted APV with EFV for
days 11 to 13 with a PK study on day 14. A second protease inhibitor (PI) (NFV, 1,250 mg, q12h; IDV, 1,200
mg, q12h; RTV, 100 mg, q12h; or SQV, 1,600 mg, q12h) was added to APV and EFV on day 15, and a PK study
was conducted on day 21. Controls continued APV and EFV without a second PI. Among subjects, the APV
areas under the curve (AUCs) on days 0, 14, and 21 were compared using the Wilcoxon signed-rank test.
Ninety-percent confidence intervals around the geometric mean ratios (GMR) were calculated. APV AUCs were
46% to 61% lower (median percentage of AUC) with EFV (day 14 versus day 0; P values of <0.05). In the NFV,
IDV, and RTV groups, day 21 APV AUCs with EFV were higher than AUCs for EFV alone. Ninety-percent
confidence intervals around the GMR were 3.5 to 5.3 for NFV (P < 0.001), 2.8 to 4.5 for IDV (P < 0.001), and
7.8 to 11.5 for RTV (P  0.004). Saquinavir modestly increased the APV AUCs (GMR, 1.0 to 1.4; P  0.106).
Control group AUCs were lower on day 21 compared to those on day 14 (GMR, 0.7 to 1.0; P  0.042).
African-American non-Hispanics had higher day 14 efavirenz AUCs than white non-Hispanics. We conclude
that EFV lowered APV AUCs, but nelfinavir, indinavir, or ritonavir compensated for EFV induction.
The clinical use of antiretroviral regimens containing com-
binations of nucleoside reverse transcriptase inhibitors (NRTIs),
non-nucleotide reverse transcriptase inhibitors (NNRTIs), and
protease inhibitors (PI) has become the accepted approach to
therapy for human immunodeficiency virus (HIV) infection,
especially for patients with multiple prior antiretroviral regi-
mens (1, 29). This has led to the development of new antiret-
roviral treatments and clinical studies of three- and four-drug
combinations as salvage regimens for antiviral-experienced pa-
tients. While these combination regimens are often guided by
HIV-1 resistance assays, there are often incomplete pharma-
cokinetic (PK) data available to guide optimal dosing of dual
protease inhibitors in an NNRTI-containing regimen.
Due to the complex nature of drug interactions (metabolic
induction versus inhibition, efflux transporter interactions) and
the desire to understand mechanisms underlying these drug
interactions, Adult AIDS Clinical Trials Group (ACTG) pro-
tocol A5043 was developed to examine these interactions. At
the time A5043 was developed, the routine use of low-dose
ritonavir (RTV) was not considered to be the standard of care,
and the optimal approach to combining two PIs with efavirenz
(EFV) was under investigation in ACTG 398. ACTG 398 uti-
lized NNRTI-PI combinations similar to those of ACTG 5043
along with nucleoside analogs and reported 30% antiviral
responses in a group of PI-experienced patients (10). Another
clinical study was conducted in a small group of patients with
HIV-1 infection, examining two dosage regimens of reduced-
dose ritonavir in combination with amprenavir (APV), efa-
virenz, and NRTIs, indicating that efavirenz induction could be
offset by ritonavir (6). The pharmacologic objective of ACTG
5043 was to extend these studies and obtain additional data on
indinavir (IDV)-, nelfinavir (NFV)-, and saquinavir (SQV)-
containing regimens and their dosage requirements when com-
bined with amprenavir and efavirenz in HIV-seronegative sub-
jects. In addition, the inclusion of a control group that did not
have a second PI added allowed for comparison against results
obtained by continued efavirenz and amprenavir dosing.
The rationale for conducting ACTG 5043 in HIV-seroneg-
ative volunteer subjects was that stepwise introduction of a
second PI to the combination of amprenavir plus efavirenz
could be accomplished without the concern of drug concentra-
tions being less than therapeutic, which might put HIV-in-
* Corresponding author. Mailing address: Adult ACTG Pharmacol-
ogy Support Laboratory, Pharmacotherapy Research Center, Depart-
ment of Pharmacy Practice, School of Pharmacy and Pharmaceutical
Sciences, 317 Hochstetter Hall, University at Buffalo, Amherst, NY
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fected individuals at risk for the development of drug resis-
tance.
MATERIALS AND METHODS
ACTG 5043 was an open-label, pharmacokinetic study of orally administered
amprenavir 600 mg alone, followed by efavirenz 600 mg alone, followed in turn
by the combination of amprenavir added to efavirenz, which was then continued
with or without the administration of a second PI. The second PI was nelfinavir
1,250 mg every 12 h (q12h) (arm B), indinavir 1,200 mg q12h (arm C), ritonavir
100 mg q12h (arm D), or saquinavir soft gelatin capsules 1,600 mg q12h (arm E).
The following pharmacokinetic studies were conducted on three days: a 24-hour
study after the first dose of amprenavir, a 12-hour study after the attainment of
steady state on efavirenz and amprenavir (day 14), and a 12-hour study after the
attainment of steady state on the three-drug regimen (amprenavir plus efavirenz
plus a second PI) on day 21. On each study day, intravenous catheters were
placed to facilitate blood sampling. Study medications were ingested and blood
samples were collected prior to and 1, 2, 3, 4, 5, 6, 8, 10, and 12 h after dosing
(and 24 h after dosing on day 0).
Approximately 90 subjects were targeted to be enrolled in order to obtain 70
evaluable subjects with 14 per arm. Inclusion criteria were an age greater than or
equal to 18 but less than or equal to 65 years, a body weight within 20 percent of
ideal, a body weight of at least 50 kg, and HIV-1 seronegative status. Laboratory
parameters were white blood cell counts 4,000 and 1.5 times the upper limit
of normal (ULN), absolute neutrophil counts 1,500 cells/mm3 and 1.5 ULN,
hemoglobin counts 11.7 and 16 g/dl for women and 12.7 and 18 g/dl for
men, and 100,000 and 450,000 platelets/mm3. The following parameters also
applied: fasting total cholesterol and triglyceride levels, 200 mg/dl; blood urea
nitrogen level, 1.25  ULN; creatinine level, less than ULN or corresponding
to a calculated creatinine clearance of 80 ml/min; an albumin level within the
normal limits for the testing laboratory; amylase level, less than the ULN; and,
if elevated, a lipase level of less than the ULN and a pancreatic amylase level of
less than the ULN. Total bilirubin, aspartate aminotransferase (serum glutamic
oxalacetic transaminase), alanine aminotransferase (serum glutamic pyruvic
transaminase), and alkaline phosphatase levels were1.25ULN. Subjects had
the ability and willingness to sign consent forms. Exclusion criteria included the
following: reproductive potential (for women); ongoing cardiovascular, renal,
hematologic, neurologic, gastrointestinal, pulmonary, psychiatric, endocrine, or
immunologic disease or chronic ongoing gastrointestinal condition that might
interfere with drug absorption; and any other medical condition which, in the
opinion of the investigator, would interfere with the subject’s ability to partici-
pate in this protocol. Subjects were not enrolled if they received protease inhib-
itors, NNRTIs, or investigational agents within 60 days prior to study entry or any
acute therapy for an infection or other medical illness within 14 days prior to
study entry. Healthy HIV-1 seronegative adult subjects who met the eligibility
criteria signed a consent form. Subjects received their randomized study drug
assignment (arms A through E) at the first pharmacokinetic study visit.
Antiretroviral assays. Efavirenz, nelfinavir, M8 (a primary metabolite of nelfi-
navir), amprenavir, indinavir, ritonavir, and saquinavir were measured by liquid
chromatography with tandem mass spectrometry in the University at Buffalo
ACTG Pharmacology Support Laboratory with a validated assay method (7, 12).
The laboratory participates in the ACTG Pharmacology Laboratory Proficiency
Testing Program for antiretroviral drug quantitation (11). Limits of detection
were 16.3 ng/ml for amprenavir, indinavir, nelfinavir, and saquinavir, 51.2 ng/ml
for ritonavir, and 8.19 ng/ml for M8. Interassay variations for all PI analytes
measured 12%, 12%, 10%, and  8% at 48 ng/ml, 240 ng/ml, 1,200
ng/ml, and 6,000 ng/ml, respectively. Efavirenz interassay variations were 7%,
7%, and 6% at 480 ng/ml, 1,200 ng/ml, and 2,400 ng/ml, respectively; the quan-
titation limit was set at 200 ng/ml.
Primary endpoints. The areas under the curve (AUCs) of amprenavir and
efavirenz were the primary pharmacokinetic endpoints. The pharmacokinetic
parameters of the maximum concentrations of the drugs in serum (Cmax) and the
concentrations of the drugs at 12 h (C12) were also examined. Adverse reactions
with severities of grade 1 or above (grade 1), as defined by the DAIDS toxicity
tables, were monitored by the study team, and those that could not be directly
attributed to a cause other than study treatment were identified as such. For each
regimen within each treatment arm, the number of grade 1 rashes and the
number of grade2 reactions of other kinds were counted, as was the proportion
of subjects evidencing such reactions. At the time of protocol development,
concern about the possible occurrence of moderately severe rashes prompted the
inclusion of the safety criterion that any subject developing a rash (not clearly
attributable to a cause other than a study drug) was to be immediately discon-
tinued from the study.
Predose fasting biochemistry and endocrine evaluations were performed at all
three pharmacokinetic study visits and at the final safety visit. These included
measurements of glucose, insulin, C peptide, triglyceride, total cholesterol, and
high-density lipoprotein cholesterol. At all three PK visits, glucose and insulin
were also measured 2 h after the ingestion of the study medications and the
protocol-specified breakfast. The lipid and endocrine data will be the subject of
a separate report.
Statistical and pharmacokinetic analysis. Sample size calculations were based
on a two-sided paired t test, with the type I error rate set to 5%, assuming a
within-subject coefficient of variation (CV) in AUC of 20% for amprenavir. A
sample size of 12 eligible subjects per arm provided 80% power to detect a 25%
difference in AUCs (e.g., the percent change in the amprenavir AUCs without
versus with the coadministration of a second PI). Accrual targets were set to 14
subjects per arm; the additional 2 subjects per arm were a buffer against adher-
ence, sample, or assay problems not detected until after study closure. Only
subjects who were able to provide pharmacokinetic data on all three study days
were included in the statistical analysis of pharmacokinetic parameters. Through-
out most of the study, subjects who discontinued early were replaced; due to slow
accrual, however, a compromise between full accrual and provision of timely
results was accepted, and accrual was closed before all targets were met. The
final counts of subjects eligible for PK analysis on arms A through E were 11, 12,
13, 9, and 10, respectively, yielding detectable changes in APV AUCs ranging
from 24% (arm C) to 29% (arm D).
A model-independent method was used to determine pharmacokinetic param-
eters using standard noncompartmental techniques (WinNonlin) based on indi-
vidual subject concentration time profiles. In each arm, differences between APV
and efavirenz (EFV) AUCs on days 21 and 14 were of primary interest and were
evaluated using the nonparametric Wilcoxon signed-rank test. PK interactions
were also evaluated using the Food and Drug Administration-recommended
method for testing bioequivalence (3, 4). For each agent and pair of study days,
the geometric mean of within-subject ratios was calculated along with the asso-
ciated 90% confidence interval (CI). To compare AUCs across groups of subjects
(those who did versus did not experience certain categories of toxicities or belong
to certain racial/ethnic groups), the Wilcoxon rank sum and Kruskal-Wallis tests
were used. Two-sided P values were considered throughout. As each arm was
considered a separate experiment, no adjustments were made for multiple com-
parisons.
RESULTS
Subjects and tolerance of study medications. Eighty-five in-
dividuals were enrolled, of whom 82 received some study drug.
Fifty-nine of these completed all three pharmacokinetic assess-
ments; however, due to dosing errors, only 56 were included in
pharmacokinetic analyses. Distributions by age, sex, and race
were similar for the 56 subjects who were included in the
pharmacokinetic analyses and for the 26 who were not. All but
one were between 18 to 49 years old, and 54 of 56 were male.
The study medications were generally well tolerated; how-
ever, a wide variety of adverse events was reported, including
a notable number of central nervous system effects, causing
many subjects to be discontinued. Table 1 summarizes the
toxicity data. Rash was not a major problem, with only nine
subjects (11% of 82 receiving any medication) reporting the
onset of rashes, all of which were of grade 1. Four rashes
occurred during dosing with EFV alone (before a second dose
of amprenavir was given), one occurred on day 5, and three
occurred on day 9 or 10. However, median day 0 amprenavir
AUCs were not significantly different between subjects with
rashes and those without rashes. The remaining five rashes
occurred 1 day into APV-plus-EFV dosing (two subjects), 1
day into APV-plus-EFV-plus-IDV dosing (one subject), 10
days into APV-plus-EFV-plus-SQV dosing (one subject), and
3 days after discontinuation of APV plus EFV plus IDV. Me-
dian day 14 efavirenz AUCs were significantly different be-
tween subjects with rashes and those without rashes (81.3 g ·
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h/ml [n  4; range, 37.7 to 160.6] and 37.5 g · h/ml [n  59;
range, 20.5 to 169.0], respectively; exact Wilcoxon rank sum P
value  0.035). Medications in subjects with rash (except for
one case of topical irritation attributable to a cause other than
a study drug) were promptly discontinued and the rashes re-
solved. Other side effects were uncommon, with two subjects
experiencing clinical chemistry abnormalities. No hematologic
abnormalities were observed. Of subjects who took any study
drug, 23 of 79 males (29%) and 0 of 3 females (0%) experi-
enced toxicities and/or discontinued early.
Among the 63 subjects for whom day 14 efavirenz AUCs
were available, 12 subjects (19%) experienced no central ner-
vous system (CNS) toxicities, 47 subjects (75%) experienced
one or more CNS toxicities of grade 1, and 4 subjects (6%)
experienced one or more CNS toxicities with maximums of
grade 2. Median efavirenz AUCs in these three groups were
42.6, 37.7, and 36.7 g · h/ml, respectively. According to the
Kruskal-Wallis (three groups) and exact two-sided Wilcoxon
rank sum (no versus some toxicity) tests, there were no statis-
tically significant differences in efavirenz AUCs between these
groups (P  0.778 and 0.883, respectively).
Pharmacokinetics. (i) Amprenavir. The pharmacokinetics of
amprenavir, as illustrated by changes in AUC, are summarized
in Tables 2 and 3. Figure 1 provides the median (25th to 75th
percentile) amprenavir plasma concentrations on days 14 and
21 for each arm. After 13 days of efavirenz dosing, the median
amprenavir AUC decreased an average of 52% across arms,
ranging from 46% (arm A) to 61% (arm D). After 20 days of
efavirenz coadministration, the median amprenavir AUC de-
creased 62% relative to that of amprenavir alone (no second
PI; day 0). Compared with amprenavir AUCs on day 0, nelfi-
navir (arm B) led to a 107% median increase, indinavir (arm
C) led to a 60% median increase, ritonavir (arm D) led to a
288% increase, and saquinavir (arm E) resulted in no signifi-
cant change. Amprenavir AUCs were higher on day 21 than on
day 0 in 100%, 85%, and 100% of subjects in the nelfinavir,
indinavir, and ritonavir arms, respectively. Relative to the am-
prenavir AUC after 14 days of efavirenz coadministration, the
second protease inhibitor was associated with percentage
changes in the amprenavir AUCs of 20.04, 315.74,
291.83, 888.40, and  17.56% for no second PI, nelfinavir,
indinavir, ritonavir, and saquinavir, respectively. Ninety-per-
cent CIs around geometric mean ratios were as follows: 3.5 to
5.3 for nelfinavir (P  0.001), 2.8 to 4.5 for indinavir (P 
0.001), and 7.8 to 11.5 for ritonavir (P  0.004). The addition
of saquinavir resulted in a change in the amprenavir AUC that
was at the margin of statistical significance (GMR, 1.0 to 1.4;
P  0.106). AUCs in the control group were slightly lower on
day 21 than on day 14 (Table 3).
(ii) Efavirenz. Ninety-percent CIs around the EFV geomet-
ric mean ratios (days 21 and 14) for arms A through E were as
follows: 0.78 to 1.05, 0.91 to 1.06, 0.78 to 0.97, 0.82 to 1.08, and
0.80 to 0.97, respectively (Fig. 2).
(iii) Pharmacokinetics of second PI. The pharmacokinetics
of the second PIs are summarized in Table 4. The median
AUCs for nelfinavir, indinavir, ritonavir, and saquinavir were
26.46, 18.79, 3.21, and 2.81 g · h/ml, respectively. Median
Cmax values were 3.80, 5.95, 0.59, and 0.99 g/ml, respectively.
Median C12 values were 0.89, 0.04, 0.09, and 0.04, g/ml, re-
spectively. The ratio of the AUC of M8 to that of nelfinavir is
described in Table 4.
Race/ethnicity relationships. Among 82 subjects who took
any study drug, 61 were white non-Hispanic and 16 were Af-
rican-American non-Hispanic. The remaining five subjects, of
whom two were Hispanic and three were Asian/Pacific Is-
lander, were not considered in the following analyses. There
was no statistically significant association between race/ethnic-
ity and day 0 amprenavir AUCs or between racial group and
day 14 amprenavir AUCs. However, African-American non-
Hispanics had significantly higher day 14 efavirenz AUCs than
TABLE 1. Proportions of subjects evidencing toxicities among those who had treatment dispensed and those with three evaluable
pharmacokinetics studies
Toxicity














Subjects receiving treatment 0/16 (0) 1/18 (6) 0/18 (0) 1/15 (7) 0/15 (0) 2/82 (2)
PK completers 0/11 (0) 0/12 (0) 0/13 (0) 1/10 (10) 0/10 (0) 1/56 (2)
Grade 1 rash in:
Subjects receiving treatment 2/16 (13) 1/18 (6) 3/18 (17) 1/15 (7) 2/15 (13) 9/82 (11)
PK completers 0/11 (0) 0/12 (0) 2/13 (15) 0/10 (0) 0/10 (0) 2/56 (4)
Grade 2 CNSb in:
Subjects receiving treatment 2/16 (13) 1/18 (6) 2/18 (11) 2/15 (13) 3/15 (20) 10/82 (12)
PK completers 0/11 (0) 0/12 (0) 0/13 (0) 2/10 (20) 0/10 (0) 2/56 (4)
Grade 2 signs/symptomsc in:
Subjects receiving treatment 0/16 (0) 2/18 (11) 2/18 (11) 2/15 (13) 1/15 (7) 7/82 (9)
PK completers 0/11 (0) 2/12 (17) 1/13 (8) 1/10 (10) 1/10 (10) 5/56 (9)
a There were no grade 2 hematology adverse events.
b One subject experienced a grade 3 CNS toxicity (excessive rage) after a single dose of amprenavir, at which time the site ascertained that the subject had prior
depression that would interfere with his study participation. This subject was discontinued from study drug, was followed up for safety on day 25, and is excluded from
the analysis presented here.
c Excluding rash and CNS events.
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white non-Hispanics: the median efavirenz AUCs were 49.0
and 37.6 g · h/ml, respectively (exact two-sided Wilcoxon rank
sum P value  0.025), as shown in Fig. 3.
DISCUSSION
At the time ACTG 5043 was conducted, the routine use of
low-dose ritonavir was uncommon, but the desire to optimize
individual protease inhibitor pharmacokinetics was under ac-
tive investigation. The use of efavirenz combined with PIs was
also under investigation in clinical trials for patients failing PI
therapy (6, 9, 10). In addition, the need for salvage therapy
protocols often preceded the availability of intensive three-way
drug interaction studies, and it was common to include phar-
macokinetic substudies as means of determining complex in-
teractions. In contrast, conducting pharmacokinetic studies in
seronegative subjects may provide an opportunity to examine
three-way drug interactions without the potential for the de-
velopment of resistance. On the other hand, the data from this
type of study design may not be directly applicable to HIV-
infected patients who have coinfective hepatitis B and/or C due
to altered metabolic capacities.
Safety and tolerability. Pharmacokinetic studies of antiret-
roviral agents in HIV-seronegative subjects have merit because
short durations and sequential additions of antiretroviral med-
ications can be evaluated without concern for the development
of drug-resistant virus in HIV-infected individuals. Further,
TABLE 2. Amprenavir pharmacokinetics: summary statistics for amprenavir AUCs and Cmax and C12 values
a
Arm PK parameter Study day Codrug(s) No. Mean SD CV (%) Median Range
A AUC 0 11 9.23 3.97 43.0 8.87 3.61–15.01
14 EFV 11 5.09 3.34 65.6 5.46 0.79–10.79
21 EFV 11 3.94 2.08 52.7 4.37 0.51–7.51
Cmax 0 11 2.61 1.19 45.6 2.59 0.96–5.33
14 EFV 11 2.20 1.64 74.9 2.26 0.41–5.19
21 EFV 11 1.59 0.88 55.4 1.82 0.22–3.09
C12 0 11 0.14 0.11 73.0 0.11 0.05–0.38
14 EFV 8 0.06 0.03 54.3 0.05 0.03–0.12
21 EFV 9 0.04 0.03 72.5 0.03 0.02–0.11
B AUC 0 12 7.20 3.65 50.7 7.06 2.43–15.90
14 EFV 12 3.82 2.13 55.6 3.30 1.26–8.97
21 EFVNFV 12 15.89 7.18 45.2 14.06 6.65–31.14
Cmax 0 12 2.28 1.00 43.9 2.06 0.73–4.16
14 EFV 12 1.55 0.79 50.7 1.54 0.43–3.51
21 EFVNFV 12 2.76 0.97 35.0 2.65 1.30–4.60
C12 0 11 0.14 0.13 90.4 0.09 0.03–0.49
14 EFV 9 0.06 0.03 46.1 0.05 0.03–0.11
21 EFVNFV 12 0.42 0.34 81.6 0.32 0.06–1.18
C AUC 0 13 9.11 6.08 66.7 7.91 2.08–23.62
14 EFV 13 4.80 3.58 74.7 4.48 0.82–13.47
21 EFVIDV 13 14.88 8.42 56.6 14.20 3.98–31.65
Cmax 0 13 2.39 1.19 49.5 2.12 0.85–4.59
14 EFV 13 1.63 1.00 61.3 1.46 0.47–3.51
21 EFVIDV 13 3.54 1.47 41.6 3.22 1.18–6.51
C12 0 13 0.16 0.13 85.4 0.09 0.04–0.49
14 EFV 9 0.05 0.06 117.4 0.03 0.02–0.20
21 EFVIDV 12 0.12 0.09 81.3 0.10 0.02–0.35
D AUC 0 9 9.59 4.13 43.1 10.27 1.92–14.13
14 EFV 9 3.56 1.39 39.0 4.11 1.59–5.71
21 EFVRTV 9 32.86 11.49 35.0 32.46 16.70–55.98
Cmax 0 9 2.70 1.29 47.9 2.84 0.50–4.67
14 EFV 9 1.48 0.70 47.0 1.47 0.50–2.22
21 EFVRTV 9 4.25 1.41 33.1 4.00 2.53–7.42
C12 0 9 0.14 0.09 66.4 0.12 0.03–0.31
14 EFV 6 0.03 0.01 24.0 0.03 0.03–0.05
21 EFVRTV 9 1.72 0.68 39.8 1.32 1.04–2.85
E AUC 0 10 7.26 2.81 38.8 6.92 3.93–10.82
14 EFV 10 3.52 1.43 40.6 3.80 1.50–5.82
21 EFVSQV 10 4.40 2.43 55.3 4.61 1.91–10.17
Cmax 0 10 2.16 1.01 46.9 1.77 1.05–4.34
14 EFV 10 1.56 0.75 48.3 1.51 0.63–3.00
21 EFVSQV 10 1.55 0.95 61.3 1.29 0.68–3.73
C12 0 10 0.10 0.06 60.0 0.09 0.03–0.23
14 EFV 7 0.04 0.03 72.7 0.03 0.01–0.09
21 EFVSQV 7 0.04 0.03 77.9 0.03 0.01–0.11
a AUCs in g · h/ml; Cmax and C12 values in g/ml.
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the influence of concurrent viral infection on toxicity assess-
ment is eliminated. However, previous studies of amprenavir
pharmacokinetics in HIV-seronegative subjects showed fre-
quent rashes, including grade 3 rashes (27). In contrast, other
studies in healthy volunteers and clinical studies with amprena-
vir in HIV-infected patients indicate that the drug is well tol-
erated when administered for long periods of time, although
cutaneous reactions were the most common adverse experi-
ences reported by clinical investigators as possibly due to am-
prenavir. There was an overall incidence of rash in 19% of
subjects enrolled in phase II/III trials (20, 21, 23, 24, 26). We
found an overall rash rate of 11% in A5043, and none of the
rashes were greater than grade 1. We noted no relationship
between rash occurrence and amprenavir plasma concentra-
tions, but we noted higher EFV concentrations in subjects
exhibiting rash.
In our study, efavirenz concentrations did not correlate with
CNS symptoms, possibly because subjects with more-severe
CNS toxicities dropped out before the efavirenz AUCs were
obtained on day 14. This conjecture is supported by the fact
that efavirenz AUCs were available for 93% (13/14) of those
without CNS toxicities, 85% (47/55) of those with CNS toxic-
ities of grade 1, and only 40% (4/10) of those with one or more
CNS toxicities of grade 2.
Drug interaction pharmacokinetics. ACTG 5043 confirmed
the previously reported low plasma concentrations of am-
prenavir that are observed during the latter portion of a 12-
hour dosing period secondary to the induction effects of efa-
virenz on amprenavir (5, 6, 14). Prior studies indicate that
induction and inhibition are mediated by cytochrome P4503A4
effects (16–19). Consistent with previous reports, A5043 found
that a low dose of ritonavir could overcome the efavirenz
induction effects (14). Interestingly, the additions of other PIs
had variable effects on the amprenavir AUC in the presence of
efavirenz. When saquinavir was the second PI, this increase
was not sufficient to compensate for induction by efavirenz;
however, with the other three PIs, amprenavir concentrations
were increased markedly over those seen with amprenavir
alone. Consistent with the elevated levels of amprenavir seen
in the A5043 subjects with indinavir and nelfinavir added to
their amprenavir and efavirenz, prior pharmacokinetic studies
at weeks 2 and 24 noted that intrinsic clearance of amprenavir
was reduced by 41% and 54% by nelfinavir and indinavir,
respectively (13). In a prior study of dual PIs with efavirenz in
salvage regimens (ACTG 398), saquinavir had a minimal effect
on amprenavir clearance, similar to the results of the present
study. Amprenavir clearance was noted to increase by more
than 30% from week 2 to week 24. The mechanism for this
long-term change in exposure remains unclear but may be
partially due to additional enzyme induction after the antiviral
activity of a regimen has been maximized. This may also ex-
plain why the APV concentrations were lower on day 21 than
on day 14 in the absence of a second PI. We have recently
reported a similar finding for the effect of efavirenz on nelfi-
navir over a 32-week period (25).
In a prior study of salvage regimens containing efavirenz,
amprenavir, and a second PI (indinavir, nelfinavir, or saquina-
vir), a 30% success rate was reported (10). It is possible that
the use of higher initial doses, optimal drug combinations that
enhance PI levels, or therapeutic drug monitoring allowing
higher doses in some patients would have resulted in improved
clinical responses.
The effect of ritonavir in countering efavirenz induction has
been previously described (2, 14, 15), and the A5043 data are
consistent with these findings. In addition, Wire et al. reported
an interaction among fosamprenavir, ritonavir, and efavirenz.
Amprenavir exposure was not reduced when efavirenz was
added to fosamprenavir (700 mg twice a day [BID]) with
ritonavir (100 mg BID). However, amprenavir exposure was
reduced when efavirenz was added to fosamprenavir (1,400 mg
once a day) with ritonavir (100 mg once a day). Because lower
plasma amprenavir trough concentrations are observed with
the regimen of one daily dose, these results suggest that plasma
ritonavir concentrations must be maintained at levels necessary
to counteract the induction effects of efavirenz. Given the
rapid and nearly complete conversion of fosamprenavir to am-
TABLE 3. Comparison of amprenavir AUCs in each arm





A Day 14 to day 0 46.21 0.34, 0.65 0.0020 0.0016
Day 21 to day 14 20.04 0.69, 0.97 0.0420 0.0690
Day 21 to day 0 61.75 0.27, 0.53 0.0010 0.0004
B Day 14 to day 0 48.42 0.44, 0.63 0.0005 0.0002
Day 21 to day 14 315.74 3.52, 5.27 0.0005 0.0001
Day 21 to day 0 107.17 1.66, 3.12 0.0005 0.0014
C Day 14 to day 0 53.11 0.35, 0.66 0.0017 0.0034
Day 21 to day 14 291.83 2.83, 4.47 0.0002 0.0001
Day 21 to day 0 59.65 1.24, 2.36 0.0017 0.0037
D Day 14 to day 0 61.34 0.31, 0.50 0.0039 0.0005
Day 21 to day 14 888.40 7.83, 11.47 0.0039 0.0001
Day 21 to day 0 287.78 2.73, 5.07 0.0039 0.0001
E Day 14 to day 0 51.05 0.32, 0.71 0.0059 0.0059
Day 21 to day 14 17.56 1.00, 1.45 0.1055 0.1509
Day 21 to day 0 42.69 0.37, 0.89 0.0645 0.0540
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prenavir in vivo and the similarity of metabolic drug interac-
tion data, drug interaction data from amprenavir may be rea-
sonably applied to fosamprenavir (28).
In a prior study (ACTG 398), nelfinavir and indinavir in-
creased plasma amprenavir exposure to similar extents,
whereas saquinavir was associated with an increase of marginal
significance. The “pharmacokinetic-enhancing” effects of nelfi-
navir and indinavir on plasma amprenavir exposure (in com-
bination with efavirenz) also appeared to be greater in the
present study (200% versus 300%). Several factors associ-
ated with A5043 may account for the apparent greater magni-
tude of boosting, such as the shorter duration of amprenavir
dosing in combination with the second PI (7 days versus 14
days), the lower amprenavir dose (600 mg BID versus 1,200 mg
BID), the use of uninfected subjects, and the use of intrasu-
bject comparisons. It is interesting that an increased amprena-
vir exposure in A5043 was also observed in combination with
nelfinavir and indinavir (both in combination with efavirenz) as
in a prior report (ACTG 398). With regard to the plasma
pharmacokinetic parameters for the second PI in A5043, val-
ues appeared to be within the range reported in other studies.
Similar to what has been seen in other reports, none of the
FIG. 1. Arm-specific amprenavir concentrations by sample time when amprenavir is coadministered with EFV and with EFV plus a second PI.
For each arm separately, median amprenavir concentrations are plotted against (offset) scheduled sample times when subjects had taken APV plus
EFV only (day 14) and when subjects had taken APV plus EFV and (on all but arm A) a second protease inhibitor (day 21). Error bars indicate
the 25th and 75th percentiles of amprenavir concentrations. So that the day 14 and 21 points can be distinguished, they are offset slightly to the
left and right, respectively.
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various A5043 study arms appeared to have significant effects
on plasma efavirenz exposure; however, efavirenz concentra-
tions were higher in African-Americans. Higher plasma con-
centrations and increased CNS toxicity from efavirenz have
been observed in African-Americans in recent clinical studies
(22). These increased concentrations are thought to result
from altered efavirenz metabolism. Polymorphisms in CYP
2B6, more common in African-Americans, result in reduced
metabolism of efavirenz with consequent higher plasma con-
centrations (2, 8). This should be considered when EFV is
prescribed for African-Americans.
In considering the possible mechanisms that may be under-
lying these three-way interactions, it is likely that efavirenz
induces CYP4503A induction in hepatocytes (and possibly in-
testinal endothelial cells), which accounts for the lower plasma
concentrations of amprenavir following coadministration with
efavirenz. If this is the case, then the addition of a 3A4 inhib-
itor would be expected to counter, to some degree, the greater
metabolic capacity induced by efavirenz. This was the case for
each of the protease inhibitors (except saquinavir) as follows:
for indinavir to a lesser extent than for nelfinavir, and for
nelfinavir to a lesser extent than for ritonavir. Although nelfi-
navir and indinavir provide increases in plasma amprenavir
exposure, they are not as potent as low-dose ritonavir. How-
ever, full doses of these agents would be expected to provide
additional virologic activity, whereas low-dose ritonavir does
not.
In summary, there still exists some uncertainty as to whether
the incidence of amprenavir-associated rash among HIV-sero-
negative volunteers is a significant barrier to conducting mech-
anistic studies. Observations from some studies suggest that
prior exposure to ritonavir or lopinavir-ritonavir seems to re-
duce the occurrence of amprenavir-associated rash (27). A
similar finding when investigating delavirdine with ritonavir
FIG. 2. Efavirenz bioequivalence results for each arm showing the geometric mean of within-subject ratios (EFV AUC with APV  a second
PI/EFV AUC with APV only; days 21 and 14) and the associated 90% confidence intervals. Lower and upper dashed lines represent the no-effect
boundaries of 80% to 125%. Reference lines for 62.5% and 160.0% are also shown.
FIG. 3. Box plot of day 14 efavirenz AUCs in white non-Hispanic
and black non-Hispanic subjects. The height of each box represents the
interquartile range (the distance between the 25th and the 75th per-
centiles), the horizontal lines in the box interiors represent the medi-
ans, and the vertical lines issuing from the boxes extend to the most
extreme data points that are within 1.5 times the interquartile ranges
of the boxes. The circles represent points outside these ranges.
TABLE 4. Pharmacokinetics of second protease inhibitors:
summary statistics for AUCs, for Cmax and C12 values, and for the
ratio of AUCs for M8 and NFVa
Analyte Parameter No. Mean SD CV (%) Median Range
NFV AUC 12 31.13 12.83 41.2 26.46 18.40–65.46
Cmax 12 4.34 1.45 33.4 3.80 2.95–7.95
C12 12 1.11 0.81 72.9 0.89 0.37–3.33
M8 AUC 12 5.72 2.95 51.7 5.86 1.10–11.02
Cmax 12 0.88 0.36 41.3 0.86 0.24–1.53
C12 12 0.16 0.13 81.9 0.12 0.01–0.44
M8:NFV AUC 12 0.19 0.09 46.7 0.17 0.05–0.33
IDV AUC 13 19.57 6.75 34.5 18.79 8.76–34.37
Cmax 13 6.77 2.40 35.5 5.95 3.27–11.30
C12 13 0.05 0.03 55.5 0.04 0.02–0.11
RTV AUC 10 3.22 1.11 34.5 3.21 1.46–5.37
Cmax 10 0.63 0.26 41.9 0.59 0.31–1.09
C12 9 0.10 0.06 62.8 0.09 0.03–0.24
SQV AUC 10 3.19 1.60 50.0 2.81 1.23–7.23
Cmax 10 1.01 0.46 45.7 0.99 0.44–2.09
C12 10 0.04 0.03 69.2 0.04 0.02–0.12
a AUCs in g · h/ml; Cmax and C12 values in g/ml.
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was observed (25), suggesting that an intermediate metabolite
may mediate the hypersensitivity. This remains an important
area of clinical investigation, since new interactions with fos-
amprenavir will require in-depth drug interaction studies, es-
pecially in dual-PI regimens with ritonavir pharmacokinetic
enhancement. Conducting this three-way interaction study in
seronegative volunteers was a safe and ethical alternative to
studying HIV-infected patients and allowed a more robust
study methodology to investigate these complex interactions by
a crossover (within-subject) design. These data indicate that PI
dosing may not be readily predicted from in vitro inhibition
data and that clinical pharmacokinetic studies are required
when dual PIs are combined with an inducing NNRTI, such as
efavirenz.
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